Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
There was a lot of hype and excitement around gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) last year after it obtained approval for its first product, Casgevy. But that excitement has largely waned, and investors appear to have moved on from the stock. Year to date, shares of CRISPR are down 24%, and it is nowhere near its 52-week high of more than $91.
Is there something wrong with the business, or could the decline in price make CRISPR a potential steal of a deal?
Casgevy is a gene-editing therapy which could be a game changer for CRISPR's business. The one-time treatment for sickle cell disease and beta thalassemia can generate billions in revenue, but the problem is that it could take a while for the rollout.
Source Fool.com
